Literature DB >> 26537853

Impact of Prostate Cancer Treatment on the Sexual Quality of Life for Men-Who-Have-Sex-with-Men.

Tsz Kin Lee1, Ariel Baker Handy2, Winkle Kwan1, John Lindsay Oliffe3, Lori Anne Brotto2, Richard Joel Wassersug4, Gary Wayne Dowsett5.   

Abstract

INTRODUCTION: With earlier prostate cancer (PCa) diagnosis and an increased focus on survivorship, post-treatment sexual quality of life (QoL) has become increasingly important. Research and validated instruments for sexual QoL assessment based on heterosexual samples have limited applicability for men-who-have-sex-with-men (MSM). AIM: We aimed to create a validated instrument for assessing sexual needs and concerns of MSM post-PCa treatment. Here we explore post-PCa treatment sexual concerns for a sample of MSM, as the first part of this multi-phase project.
METHODS: Individual semi-structured interviews were conducted with 16 MSM face-to-face or via Internet-based video conferencing. Participants were asked open-ended questions about their experiences of sexual QoL following PCa. Interviews were recorded, transcribed verbatim, uploaded to NVivo 8(TM) , and analyzed using qualitative methodology. MAIN OUTCOME MEASURE: We have conducted semi-structure qualitative interviews on 16 MSM who were treated for PCa. Focus was on post-treatment sexual concerns.
RESULTS: The following themes were inductively derived: (i) erectile, urinary, ejaculation, and orgasmic dysfunctions; (ii) challenges to intimate relationships; and (iii) lack of MSM-specific oncological and psychosocial support for PCa survivorship. Sexual practices pre-treatment ranked in order of frequency were masturbation, oral sex, and anal sex, an ordering that prevailed post-treatment. Sexual QoL decreased with erectile, urinary, and ejaculation dysfunctions. Post-treatment orgasms were compromised. Some single men and men in non-monogamous relationships reported a loss of confidence or difficulty meeting other men post-treatment. Limited access to targeted oncological and psychosocial supports posed difficulties in coping with PCa for MSM.
CONCLUSIONS: The negative impact on sexual QoL can be severe for MSM and requires targeted attention. Penile-vaginal intercourse and erectile function have been the primary focus of sexual research and rehabilitation for men with PCa, and do not adequately reflect the sexual practices of MSM. Our findings suggest that future research dedicated to MSM with PCa is needed to incorporate their sexual practices and preferences specifically into treatment decisions, and that targeted oncological and psychosocial support services are also warranted.
© 2015 International Society for Sexual Medicine.

Entities:  

Keywords:  Gay Men; Homosexual; Men-Who-Have-Ssex-with-Men; Prostate Cancer; Qualitative Study; Quality of Life; Sexual Dysfunction; Survivorship

Mesh:

Year:  2015        PMID: 26537853     DOI: 10.1111/jsm.13030

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  11 in total

Review 1.  Prostate Cancer Patient Perspectives on the Use of Information in Treatment Decision-Making: A Systematic Review and Qualitative Meta-synthesis.

Authors:  Sujane Kandasamy; Ahmad Firas Khalid; Umair Majid; Meredith Vanstone
Journal:  Ont Health Technol Assess Ser       Date:  2017-05-01

2.  Influence of anticancer agents on sexual function: An in vivo study based on the US FDA Adverse Event Reporting System.

Authors:  Tomoya Kataoka; Akimasa Sanagawa; Jun Suzuki; Tatsuya Muto; Yuji Hotta; Yoshihiro Kawade; Yasuhiro Maeda; Masahiro Tohkin; Kazunori Kimura
Journal:  Andrology       Date:  2021-08-31       Impact factor: 4.456

Review 3.  Supportive care needs of men with prostate cancer: A systematic review update.

Authors:  Jai Prashar; Patricia Schartau; Elizabeth Murray
Journal:  Eur J Cancer Care (Engl)       Date:  2022-01-17       Impact factor: 2.328

4.  Prostate cancer disclosure and sexual orientation: Understanding outness to healthcare providers as a situational or consistent phenomenon.

Authors:  Daniel R Wells-Prado; Michael W Ross; B R Simon Rosser; Elizabeth J Polter; Bea D Capistrant; Ryan Haggart; Nidhi Kohli; Badrinath R Konety; Darryl Mitteldorf; Kristine M C Talley; William West; Christopher W Wheldon
Journal:  Patient Educ Couns       Date:  2021-11-24

Review 5.  Prostatic irradiation-induced sexual dysfunction: A review and multidisciplinary guide to management in the radical radiotherapy era (Part III on Psychosexual Therapy and the Masculine Self-Esteem).

Authors:  Marigdalia K Ramirez-Fort; Paula Suarez; Margely Carrion; Daniel Weiner; Claire Postl; Ricardo Arribas; Mehdi Sayyah; Digna V Forta; M Junaid Niaz; Amir Feily; Christopher S Lange; Zhahedia Zhaythseff Fort; Migdalia Fort
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-30

Review 6.  Cancer in Sexual and Gender Minority Patients: Are We Addressing Their Needs?

Authors:  Elizabeth J Cathcart-Rake
Journal:  Curr Oncol Rep       Date:  2018-09-13       Impact factor: 5.075

7.  Understanding Prostate Cancer in Gay, Bisexual, and Other Men Who Have Sex with Men and Transgender Women: A Review of the Literature.

Authors:  B R Simon Rosser; Shanda L Hunt; Benjamin D Capistrant; Nidhi Kohli; Badrinath R Konety; Darryl Mitteldorf; Michael W Ross; Kristine M Talley; William West
Journal:  Curr Sex Health Rep       Date:  2019-11-08

8.  The Experiences of Gay and Bisexual Men Post-Prostate Cancer Treatment: A Meta-Synthesis of Qualitative Studies.

Authors:  Obrey Alexis; Aaron James Worsley
Journal:  Am J Mens Health       Date:  2018-08-16

9.  Improving the Clinical Treatment of Vulnerable Populations in Radiation Oncology.

Authors:  Shearwood McClelland; Daniel G Petereit; Ross Zeitlin; Cristiane Takita; Gita Suneja; Robert C Miller; Curtiland Deville; Malika L Siker
Journal:  Adv Radiat Oncol       Date:  2020-08-06

10.  Health outcomes of sexual and gender minorities after cancer: a systematic review.

Authors:  Mandi L Pratt-Chapman; Ash B Alpert; Daniel A Castillo
Journal:  Syst Rev       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.